Related Experiment Video
Updated: Jun 13, 2026
06:30
Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock
Published on: May 19, 2022
[Perioperative beta-receptor blockade. For and against]
B Preckel1, M Poels, F Wappler
1Department of Anesthesiology, Academic Medical Centre AMC, University of Amsterdam, Meibergdreef 9, 1100 Amsterdam, The Netherlands. b.preckel@amc.uva.nl
Der Anaesthesist
|April 13, 2010
Summary
Beta-receptor blockers are no longer recommended for reducing perioperative risks, especially in low-risk patients. Recent data show no clear evidence of benefit and potential harm from these cardiac medications.
Area of Science:
- Cardiology
- Anesthesiology
- Pharmacology
Context:
- Perioperative care guidelines have evolved regarding beta-receptor blocker use.
- Previous recommendations for beta-receptor blockade in the 1990s are now under scrutiny.
- Patient risk stratification is crucial in perioperative medication management.
Purpose:
- To evaluate the current evidence for beta-receptor blockers in perioperative morbidity and mortality reduction.
- To assess the efficacy and safety of beta-receptor blockade in patients with varying cardiac risk.
- To inform clinical practice regarding the use of beta-receptor blockers in the perioperative setting.
Summary:
- Recent studies challenge the routine use of beta-receptor blockers for perioperative outcomes.
- Evidence does not support beta-receptor blockade for reducing morbidity and mortality, even in high-risk patients.
- In low-risk individuals, initiating beta-receptor blockers perioperatively may increase adverse events.
Impact:
- Clinical practice may shift away from routine beta-receptor blocker administration in perioperative care.
- Revised guidelines may de-emphasize beta-receptor blockers for patients with low cardiac risk.
- Further research is needed to clarify the role of beta-receptor blockers in specific patient populations.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...